InMed Pharmaceuticals (INM) Competitors $2.35 -0.11 (-4.47%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.05 (+2.13%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. APLM, SYBX, FNCH, PRPH, AYTU, NAII, LEXX, MTEX, EDSA, and ABPShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Apollomics (APLM), Synlogic (SYBX), Finch Therapeutics Group (FNCH), ProPhase Labs (PRPH), Aytu BioPharma (AYTU), Natural Alternatives International (NAII), Lexaria Bioscience (LEXX), Mannatech (MTEX), Edesa Biotech (EDSA), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Apollomics Synlogic Finch Therapeutics Group ProPhase Labs Aytu BioPharma Natural Alternatives International Lexaria Bioscience Mannatech Edesa Biotech Abpro InMed Pharmaceuticals (NASDAQ:INM) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership. Do institutionals & insiders hold more shares of INM or APLM? 20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to INM or APLM? In the previous week, Apollomics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.63 equaled Apollomics'average media sentiment score. Company Overall Sentiment InMed Pharmaceuticals Positive Apollomics Positive Is INM or APLM more profitable? Apollomics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -165.12%. Apollomics' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-165.12% -93.19% -74.49% Apollomics N/A N/A N/A Which has stronger earnings & valuation, INM or APLM? InMed Pharmaceuticals has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.94M1.13-$8.16M-$12.09-0.19Apollomics$1.49M13.61-$53.86MN/AN/A Do analysts recommend INM or APLM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility and risk, INM or APLM? InMed Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. SummaryApollomics beats InMed Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.87M$2.65B$6.14B$10.65BDividend YieldN/A56.72%5.66%4.70%P/E Ratio-0.1923.7585.8427.65Price / Sales1.13782.57621.60138.35Price / CashN/A177.3038.3262.20Price / Book0.355.6413.066.79Net Income-$8.16M$32.78M$3.30B$275.88M7 Day Performance3.98%6.31%4.81%2.64%1 Month Performance4.44%13.80%9.99%9.13%1 Year Performance-42.82%2.75%85.28%35.89% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.0964 of 5 stars$2.35-4.5%N/A-41.0%$5.87M$4.94M-0.1910News CoverageAnalyst ForecastShort Interest ↓APLMApollomics0.7843 of 5 stars$18.43flatN/A+29.8%$20.33MN/A0.0045Analyst ForecastGap UpSYBXSynlogic0.7514 of 5 stars$1.65-2.9%N/A+18.8%$19.32M$10K-20.6480News CoveragePositive NewsAnalyst ForecastFNCHFinch Therapeutics Group0.7706 of 5 stars$12.00-2.0%N/A+5.2%$19.27MN/A-1.36190PRPHProPhase Labs0.3595 of 5 stars$0.45+3.5%N/A-77.8%$18.82M$5.59M-0.36130Analyst ForecastGap UpAYTUAytu BioPharma3.7693 of 5 stars$1.83+7.0%$9.17+400.9%+0.9%$18.04M$66.38M-0.65160NAIINatural Alternatives International1.2652 of 5 stars$2.89-0.7%N/A-40.2%$17.86M$125.48M-1.27290Analyst ForecastLEXXLexaria Bioscience2.8903 of 5 stars$0.90-8.3%$4.00+344.0%-70.3%$17.74M$460K-1.357News CoverageAnalyst ForecastMTEXMannatech1.1058 of 5 stars$9.21+8.2%N/A+12.0%$17.50M$117.87M-4.52250Analyst ForecastGap UpEDSAEdesa Biotech3.2524 of 5 stars$2.46+0.4%$5.00+103.3%-36.2%$17.32MN/A-1.8620Positive NewsAnalyst ForecastGap DownABPAbpro3.3081 of 5 stars$0.21-16.7%$4.00+1,768.3%N/A$17.16M$183K0.0015Analyst ForecastGap Up Related Companies and Tools Related Companies APLM Alternatives SYBX Alternatives FNCH Alternatives PRPH Alternatives AYTU Alternatives NAII Alternatives LEXX Alternatives MTEX Alternatives EDSA Alternatives ABP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
